Javier Puente
@docjavip
Followers
4K
Following
7K
Media
518
Statuses
6K
Medical oncologist. Clinical researcher focused in GU tumors. Associate Professor UCM. Hospital Clinico San Carlos Madrid, Spain
Madrid
Joined December 2012
RT @tompowles1: IMVIGOR011: Atezo vs placebo in ctDNA+ve bladder ca (including -ve becoming +ve) post cystectomy hit OS/PFS. It also tracks….
0
112
0
RT @drenriquegrande: How exciting #ESMO25 looks like in thge perioperative management of #bladdercancer 🥰🥰🥰.@myESMO #IMvigor011 #EV303 . ….
0
18
0
RT @tompowles1: Perioperative EVP shows ⬆️ EFS,OS & pCR vs cystectomy alone in high risk cisplatin ineligible MIBC (KN901). Highly active s….
0
78
0
RT @AndreaNecchi: Johnson & Johnson receives U.S. FDA Priority Review for TAR-200 NDA in high-risk non-muscle invasive bladder cancer https….
jnj.com
New Drug Application supported by results from the Phase 2b SunRISe-1 study
0
18
0
RT @neerajaiims: Just came online in @TheLancet 👉Our two papers on improved OS with Enzalutamide + Talazoparib in mCRPC #ProstateCancer in….
0
60
0
RT @RodriguezFaba: Important question arised by @docjavip in the II masterclass to fill gaps in bladder cancer. ➡️how many of the ítems of….
0
3
0
RT @RodriguezFaba: Fantastic kick off of the II masterclass to discuss gaps in #Bladder cancer. First day pathology an non-Muscle invasive….
0
11
0
RT @tompowles1: Gem/cis/durvalumab is approved in the EU for muscle invasive bladder cancer (NIAGARA study). It’s the only immune therapy s….
0
63
0
RT @nataliagandur: 🌟🔵 Redefining metastatic hormone-sensitive prostate cancer.@docjavip @OncoAlert #GUARDSymposium2025. 🔹 Timing & burden d….
0
15
0
RT @tompowles1: FGFR inhibition in FGFR3 altered UC doesn’t get the attention it deserves #GUARDSymposium2025.Its data platinum refractory….
0
21
0
RT @OncoAlert: LIVE Day TWO #GUARDSymposium2025 Presentation by Dr. Matt Galsky🇺🇸 How to select patients in whom we preserve the bladder wi….
0
20
0
RT @tompowles1: With the final analysis of the last of the 1st line metastatic clear cell RCC trials combination trials it’s still fair to….
0
75
0
RT @GuardConsortium: ¡Gracias a todos por el éxito del Mentorship Meeting! Y en especial a @PBarataMD por su apoyo y su implicación. Seguro….
0
9
0
RT @OncoAlert: Join us for the GUARD Symposium🇪🇸 featuring interactive workshops where experts collaboratively discuss real-world genitouri….
0
12
0
RT @MRoupret: So proud of my team !!! 😎@EurUrolOncol we have a rise of one point of our impact factor over the last year. Congrats for the….
0
18
0
RT @TransworldHlth: 🚨Disponible el 3r Episodio de la 1ª. Ed. #TooMoreUrotelio #CáncerUrotelial ¿Un punto de inflexión en NMIBC agresivo?. @….
0
5
0
RT @GuardConsortium: 🚨 ¡Recordatorio para jóvenes adjuntos!.El 25 de junio tienes una cita con el GUARD Mentorship Meeting: una jornada pen….
guardconsortium.org
Comité científico:
0
4
0
RT @MikeSerzanMD: 🤔 Still thinking about the fantastic #KidneyCancer program from #ASCO25? . 🎙️Join international panel of experts @alerame….
ecancer.org
Dr Michael Serzan (Dana-Farber Cancer Institute, Boston, USA), Dr Javier Puente (Hospital Clínico San Carlos, Madrid, Spain), Dr Guillermo de Velasco (Un
0
5
0
RT @alerametta: Just back from #ASCO25, where I joined an @ecancer roundtable on recent updates in renal cell carcinoma. Great to exchange….
0
5
0
RT @BoschBarrera: Brutales resultados del impacto de la hora de administración de la inmunoterapia en estudio randomizado. Pocos fármacos h….
0
44
0